Nexalin Regains Nasdaq Compliance, Pursues FDA Approval, Expands South American…
What happened
Nexalin Technology announced it regained compliance with Nasdaq's minimum bid price requirement after its common stock closed above $1.00 per share for 21 consecutive trading days between August 31 and September 29, 2026,. The company also announced it is pursuing marketing authorization from the FDA for its Deep Intracranial Frequency Stimulation (DIFS) technology and secured a new distribution agreement in Brazil, which covers six additional South American countries.
From finanznachrichten.de
Why it matters
Regaining Nasdaq compliance addresses a listing requirement for Nexalin Technology, Inc. The pursuit of FDA authorization and the expansion of distribution into Brazil and other South American countries could increase the company's market reach and revenue potential.
From finanznachrichten.de
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Geode Capital ManagementSpeculative
Might see the value of their financial stake increase due to positive news regarding Nexalin's stability and market expansion.
- Renaissance TechnologiesSpeculative
Might see the value of their financial stake increase due to positive news regarding Nexalin's stability and market expansion.
Keep exploring
The entities involved
Related events
- Janux Therapeutics, Inc. was listed on the Nasdaq stock exchange on July 28, 2026.
- Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.
- Collegium Pharmaceutical was listed on Nasdaq, and Truist Financial initiated coverage on the stock.
- NervGen Pharma Corp. began utilizing Nasdaq for its at-the-market program.
- Clene Inc. submitted an NDA to the FDA seeking accelerated approval while trading on the Nasdaq exchange.